BIOMAT Database Logo BIOMAT Database Logo

Serum amino-terminal propeptide of type III procollagen and 7S domain of type IV collagen correlate with hepatic iron concentration in patients with chronic hepatitis C following alpha-interferon therapy. 2001

I Shimizu, and T Omoya, and T Takaoka, and S Wada, and H Wada, and M Taoka, and H Hayashi, and S Hayashi, and H Honda, and N Sano, and S Ito
Second Department of Internal Medicine, Tokushima University School of Medicine, Japan. shimizui@clin.med.tokushima-u.ac.jp

BACKGROUND It has been reported that chronic infection with hepatitis C virus is associated with excess iron deposits in the liver of subjects who are neither alcoholics nor recipients of blood transfusions. However, little is known about the relationship between hepatic iron concentration (HIC) and the serum levels of hepatic fibrogenesis markers, which were caused by interferon therapy for chronic hepatitis C. Therefore, changes in the serum amino-terminal propeptide of type III procollagen (P-III-P) and the 7S domain of type IV collagen (7S-IV) in 16 patients treated with alpha-interferon (IFN-alpha) were studied, and their HIC and histological assessment evaluated. Hepatic iron concentrations were measured by using liver biopsy specimens obtained before and 6 months after the cessation of treatment. RESULTS Eight subjects (50%) who had normal alanine transaminase levels at 6 months after therapy showed significantly lowered HIC, and attenuated hepatic iron staining with decreased serum levels of P-III-P and 7S-IV compared to the remaining subjects. The HIC was significantly correlated with the serum levels of P-III-P and 7S-IV in all subjects. CONCLUSIONS These findings suggest that IFN-alpha treatment may decrease stimuli for fibrogenesis, at least in part, by reducing the hepatic iron deposition in patients with chronic hepatitis C.

UI MeSH Term Description Entries
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006820 Hyaluronic Acid A natural high-viscosity mucopolysaccharide with alternating beta (1-3) glucuronide and beta (1-4) glucosaminidic bonds. It is found in the UMBILICAL CORD, in VITREOUS BODY and in SYNOVIAL FLUID. A high urinary level is found in PROGERIA. Amo Vitrax,Amvisc,Biolon,Etamucine,Healon,Hyaluronan,Hyaluronate Sodium,Hyvisc,Luronit,Sodium Hyaluronate,Acid, Hyaluronic,Hyaluronate, Sodium,Vitrax, Amo
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

I Shimizu, and T Omoya, and T Takaoka, and S Wada, and H Wada, and M Taoka, and H Hayashi, and S Hayashi, and H Honda, and N Sano, and S Ito
Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases.
January 1995, Digestive diseases and sciences,
I Shimizu, and T Omoya, and T Takaoka, and S Wada, and H Wada, and M Taoka, and H Hayashi, and S Hayashi, and H Honda, and N Sano, and S Ito
Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.
August 2001, Digestive diseases and sciences,
I Shimizu, and T Omoya, and T Takaoka, and S Wada, and H Wada, and M Taoka, and H Hayashi, and S Hayashi, and H Honda, and N Sano, and S Ito
Serum amino-terminal propeptide of type III procollagen levels in chronic pancreatitis.
March 1996, Pancreas,
I Shimizu, and T Omoya, and T Takaoka, and S Wada, and H Wada, and M Taoka, and H Hayashi, and S Hayashi, and H Honda, and N Sano, and S Ito
Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa.
August 1995, Hepatology (Baltimore, Md.),
I Shimizu, and T Omoya, and T Takaoka, and S Wada, and H Wada, and M Taoka, and H Hayashi, and S Hayashi, and H Honda, and N Sano, and S Ito
Interferon-alpha 2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepatitis B virus infection.
September 1994, Digestive diseases and sciences,
I Shimizu, and T Omoya, and T Takaoka, and S Wada, and H Wada, and M Taoka, and H Hayashi, and S Hayashi, and H Honda, and N Sano, and S Ito
Serum amino-terminal propeptide of type III procollagen in patients with hyperthyroidism or hypothyroidism during therapy.
January 1994, Thyroid : official journal of the American Thyroid Association,
I Shimizu, and T Omoya, and T Takaoka, and S Wada, and H Wada, and M Taoka, and H Hayashi, and S Hayashi, and H Honda, and N Sano, and S Ito
Increase in serum 7S domain of type IV collagen and N-terminal propeptide of type III procollagen levels with normal serum transaminase levels after long-term oral administration of Tegaful-Uracil.
October 2002, Hepatology research : the official journal of the Japan Society of Hepatology,
I Shimizu, and T Omoya, and T Takaoka, and S Wada, and H Wada, and M Taoka, and H Hayashi, and S Hayashi, and H Honda, and N Sano, and S Ito
[Interferon modulates serum concentrations of 7S domain of type IV collagen according to the pretreatment levels in patients with chronic hepatitis C].
November 2006, Rinsho byori. The Japanese journal of clinical pathology,
I Shimizu, and T Omoya, and T Takaoka, and S Wada, and H Wada, and M Taoka, and H Hayashi, and S Hayashi, and H Honda, and N Sano, and S Ito
[Type III procollagen N-terminal aminopeptide and type IV collagen 7S in pleural effusion fluid].
June 1997, Nihon Kyobu Shikkan Gakkai zasshi,
I Shimizu, and T Omoya, and T Takaoka, and S Wada, and H Wada, and M Taoka, and H Hayashi, and S Hayashi, and H Honda, and N Sano, and S Ito
Serum concentrations of carboxyl-terminal propeptide of type I procollagen, amino-terminal propeptide of type III procollagen, cross-linked carboxyl-terminal telopeptide of type I collagen, and their interrelationships in schoolchildren.
September 1997, Clinical chemistry,
Copied contents to your clipboard!